ACTILYSE®
Overview
Product overview
ACTILYSE® injection is indicated as thrombolytic treatment in acute myocardial infarction, in acute massive pulmonary embolism or fibrinolytic treatment in acute ischemic stroke.
Product key facts
Indication
For thrombolytic treatment in acute myocardial infarction, in acute massive pulmonary embolism or fibrinolytic treatment in acute ischemic stroke.
Active ingredients
Alteplase = recombinant human tissue-type plasminogen activator
Legal category
Prescription only medicine
Concentration
Reconstituted solution consists of 1mg/mL ACTILYSE®
Administration form
Intravenous bolus or infusion
Dosage form
Solution for injection and infusion
Pack sizes
Single pack:
50 mg: 1 vial with 50 mg powder for solution for injection and 1 vial with 50 ml of water for injections.
20 mg: 1 vial with 20 mg powder for solution for injection and 1 vial with 20 ml of water for injections.
Reference:
-
ACTILYSE® Injection, approved package insert. Updated April 2019. Approved September 2019.
![[BI Medical] NOAC於AF併有CAD在真實世界的臨床效益](/tw/sites/default/files/2023-05/8-SC-TW-00435.png "[BI Medical] NOAC於AF併有CAD在真實世界的臨床效益")
![[BI Medical] NOAC於AF併有CAD在真實世界的臨床效益](/tw/sites/default/files/styles/bi_gds_medium/public/2023-02/arrow.png "[BI Medical] NOAC於AF併有CAD在真實世界的臨床效益"){kind=icon}
